Trastuzumab binds HER2 on tumor cells and its Fc engages FcγR-expressing effector cells (e.g., NK cells) to trigger antibody-dependent cellular cytotoxicity (ADCC), leading to target-cell killing; signaling blockade also contributes to growth inhibition.